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Background: In this study we assess the prevalence, characteristics as well as socio-demographic and clinical
correlates of a positive screen for HIV-associated dementia in a group of patients on antiretroviral therapy (ART) in
Bamenda, Cameroon.
Methods: In a cross-sectional study, a structured questionnaire was used to collect data on 400 patients attending
the Bamenda Regional Hospital AIDS-treatment Centre. Patients were assessed for neurocognitive function using
the International HIV Dementia Scale (IHDS) to assess finger-tapping (FT), alternating hand sequence (AHS) and a
4-word recall (4WR), each scored on a maximum of four.
Results: A total of 297 (74%) participants were females. The total IHDS score ranged from 6–12 with a mean of 9.02
and 85% of subjects screened positive for dementia (≤10 on IHDS). Participants performed worst in the AHS
assessment with a mean of 2.25 (IQR: 2–3). In multivariable analyses, screening positive for dementia was
significantly associated with having primary education or less (aOR: 8.33, 95%CI: 3.85, 16.67), and having HIV
symptoms (aOR: 12.16, 95%CI: 3.08, 48.05).
Conclusions: A very high proportion of patients on ART screened positive for dementia using the IHDS. This could
potentially be an indication of a high prevalence of HIV-associated neurocognitive disorders in this population and
or a poor performance of the IHDS in patients on ART. Future studies will need to assess the validity of the IHDS in
this population of patients on ART and also evaluate long term outcomes in patients with positive dementia
screens.
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HIV infection often results in a spectrum of neuro-
cognitive disorders, referred to as HIV-associated neu-
rocognitive disorders (HAND), which need to be
diagnosed and appropriately managed early [1,2]. While
these disorders may result directly from the effects of
HIV infection on the central nervous system, their clin-
ical manifestation, and thus diagnosis, may be impacted* Correspondence: atashili@yahoo.ie
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reproduction in any medium, provided the orby the overall clinical and neurological status of the pa-
tient as well as by the use of antiretroviral therapy
(ART), some of which may have neurotoxic effects [3,4].
Systematic reviews of studies conducted worldwide
suggest a prevalence of HAND ranging from 12-56% al-
though the varying diagnostic tools used and study pop-
ulations involved limit any direct comparisons and
inferences to other study populations [5].
Little is known on the epidemiology of neurocognitive
disorders in HIV in Cameroon. A study by Njamnshi
et al. [6] reported a prevalence of 21.1% in a group of
204 HIV-positive patients in Yaounde. In a follow-upLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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neuropsychological measures in a cross-sectional study
with 44 HIV-positive adults and 44 demographically
matched HIV-negative controls, reported worse overall
cognition in the HIV-positive individuals [7]. Further-
more, significantly lower performance was seen in the
HIV-positive sample on tests of executive function,
speed of information processing, working memory, and
psychomotor speed. HIV-positive participants with AIDS
performed worse than those with less advanced HIV dis-
ease [7]. Nevertheless, data on the epidemiology of
neurocognitive disorders in HIV patients in general and
patients on ART in particular remain scarce in this re-
gion of the world.
With the goal of providing epidemiological data that
would be useful in designing guidelines for the care of
mental diseases in HIV-affected patients in resource-lim-
ited settings, we assessed the prevalence, characteristics
and demographical and clinical correlates of a positive
dementia screen in a group of patients on antiretroviral
therapy in Bamenda, Cameroon.
Methods
Ethical considerations
This study received ethical and administrative approval
respectively from the Cameroon National Ethics Com-
mittee (No. 111/CNE/SE/09), the University of North
Carolina at Chapel Hill’s Biomedical Institutional Review
Board (# 09–0852) and the Duke University Health Sys-
tem IRB (# Pro00016937); and the Ministry of Public
Health in Cameroon.
This manuscript was written following STROBE guide-
lines for the reporting of observational studies [8].
Study design and setting
We conducted a cross-sectional descriptive study as part
of a wider project to assess and adapt the diagnosis and
treatment of depression in HIV-positive patients in
Bamenda, Cameroon- the ADEPT study. Details of the
project have been described elsewhere [9,10]. In this
paper we focus on dementia screening data as well as its
correlates.
Briefly, the study was conducted in the Bamenda Re-
gional Hospital AIDS Treatment Centre (BRHATC ) – a
centre that receives close to 4000 patients per year for
routine HIV-care including follow-up by a physician and
paramedical staff.
Study population, sampling and participants
The study population was made of attendants of the
BRHATC. To be eligible participants had to be aged be-
tween 18 and 55 years, be on antiretroviral therapy,
speak English, and provide written informed consent.Severely ill patients, needing admission or not able to
freely communicate were excluded.
Participants were enrolled in the period between May
2010 and October 2010. Each participant was eligible
only once. In an attempt to get a sample representative
of all attendees to the centre and because it was not pos-
sible to recruit and satisfactorily assess all attendees on a
particular day (the daily attendance was estimated at
more than 50), participants were approached consecu-
tively as they registered at the beginning of their visit in
the centre. Once a participant agreed to participate they
were given the opportunity to undergo all study enrol-
ment processes (consent and initial identification) after
which the research assistant returned to the registration
point to recruit the next available participant. Recruit-
ment was pursued until the calculated sample size of
400 was reached.
Data collection, variables and measurements
Standardized questionnaires were used to collect data.
The questionnaires, all administered by research assis-
tants, included the following modules administered in
chronological order: the Patient Health Questionnaire 9
(PHQ-9) to screen for depressive symptoms in the past
two weeks [11]; a socio-demographic questionnaire (in-
cluding an assessment of gender, age, marital status,
education, and residence), a subjective assessment (as
“fair” or “excellent”), by the research assistant, of partici-
pant’s English proficiency; a questionnaire assessing 13
HIV-related symptoms (new or persistent headaches,
fever, oral pain, white patches in the mouth, rashes, nau-
sea, trouble with eyes, sinus infection, numbness in the
hands or feet, persistent cough, diarrhoea, weight loss,
or abnormal vaginal discharge in women); the World
Mental Health Survey Initiative Version of the World
Health Organization’s Composite International Diagnos-
tic Instrument CIDI (used to assess for lifetime depres-
sion and depression diagnosis within the preceding year)
[12]; and the International HIV Dementia scale (IHDS).
It is worth noting that it took at least 20 minutes of con-
tact between research staff and study participant before
the IHDS tool was administered, thus ensuring that par-
ticipants were sufficiently relaxed and comfortable with
the research staff before the IHDS assessments were
conducted.
The IHDS is a standardized cross-culturally assessed
tool. It was initially developed and assessed in partici-
pants from the USA and Uganda and shown to have
sensitivities and specificities of 80% and 57% and 80%
and 55% respectively using a cut-off of ≤10 [13]. The
tool consists of three assessments: an assessment of
motor speed through finger-tapping (FT); an assessment
of psychomotor speed through a defined alternating
hand sequence (AHS) that a participant is asked to
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word recall (4WR) test. FT and AHS are scored on a
five-point scale (0–4) while the 4WR is scored out of a
maximum of four points, corresponding to the number
of words correctly recalled. The IHDS has been used in
other populations in sub-Saharan Africa, including in
Cameroon [6]. We thus did not seek to re-assess its val-
idity in our study population. However, to reduce the
potential for bias in this study the assessment was made
solely by a research assistant (a nurse by profession)
trained by the study psychiatrist (BNG). The four words
“Dog”, “Hat”, “Bean”, and “Red” were used in the 4WR
assessment.Table 1 Characteristics of the overall study population
(N (%) or median (IQR))










Previously married 178 44
Never married 85 21
Education*
Primary 245 61
Greater than primary 155 39







HIV symptom score (possible range: 0–13) 5 3-6
Dementia
Screen positive, cut-off = 10 333 85
Screen positive, cut-off = 9 235 59
*Primary = 6 years or fewer; greater than primary =more than 6 years.
**In US dollars, approximation based on reported weekly expenditures in
FCFA. IQR: Interquartile range.Data management and statistical analysis
Data from the questionnaire were entered into an Epi-
Info 2000 database (WHO/CDC Atlanta, USA) and
analysed using STATA 10 (STATA corps, Dallas, TX,
USA). Participant characteristics were described using
means, medians, standard deviations and interquartile
ranges (IQRs) for continuous variables, and using abso-
lute and relative frequencies of various responses for cat-
egorical variables.
To characterize neurocognitive function, we described
the frequency of each possible response to each of the
three assessments (FT, AHS, 4WR). We also computed
the mean, median, range and IQR of the scores for each
of the three assessments.
The composite score on the IHDS was computed by
adding the scores from the three individual assessments.
Correlates of a positive dementia screen were assessed
using two methods: considering the IHDS score on a
continuous scale (a lower score indicating more im-
paired neurocognitive function) and considering it as a
binary measure with a cut-off point of 10 as used in
other settings (a score less than or equal to 10 being
considered a positive dementia screen) [13]. In consider-
ing the IHDS score as a continuous variable, the
bivariable analysis consisted of computing the mean dif-
ference (and 95% confidence interval) in the aggregate
scores between groups of participants while the multi-
variable analysis consisted of determining the adjusted
mean difference between groups using a multiple linear
regression model with IHDS score as outcome and pa-
tient characteristics considered as predictors. Predictors
were assessed for linearity before being included in the
regression model. Considering the IHDS score as a bin-
ary measure, the bivariable analysis consisted of compar-
ing the odds of having a positive screen between groups
of participants using a Mantel-Haensel Odds ratio (and
95% CI) while the multivariable analysis consisted of
computing adjusted odds ratios (aOR) using a multiple
logistic regression model with IHDS positive screen asthe outcome and patient characteristics considered as
predictors.
A sensitivity analysis was conducted to assess the po-
tential impact (on prevalence and correlates) of using an
IHDS score cut-off point of ≤9 in defining a positive
screen.
A sample size of 400 participants allowed us to esti-
mate a positive dementia screen prevalence of 50%, at a
95% confidence level, allowing for a margin of error of ±
5% and a non-response rate of 5%.
Results
Study participants
The characteristics of the 400 participants included in
this analysis are presented in Table 1. A vast majority were
females (74%) and self-declared Christians (99%). The
median age was 41 years (IQR 34–47) and 85 (21%) had
never been married. One hundred and fifty-five (39%) had
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competency being assessed as excellent in 40%. Two-
hundred and forty-four participants (61%) declared living
in an urban area and the estimated median daily expend-
iture was one US dollar (IQR 1–3).Overall IHDS score and prevalence of a positive
dementia screen
The total IHDS score ranged from 6–12 with an IQR of
8–10 and a mean score of 9.02. The prevalence of partic-
ipants with a positive screen was respectively 85% and
59% when cut-offs of ≤10 and ≤9 were used.Characteristics of dementia screen
Of the three assessments, participants performed worst
in the AHS assessment (Table 2). The mean score in the
AHS assessment was 2.25 with an IQR: 2–3. Most par-
ticipants (62%) could complete only two alternating
hand sequences in 10 seconds. The performance in the
4WR assessment was relatively better with a mean score
of 3.28 and an IQR of 3–4. Only 46% could recall all
four words in the 4WR assessment. The best perform-
ance was obtained in the FT assessment with a mean
score of 3.49 and an IQR of 3–4. Approximately half
(51%) of participants could complete 15 or more fingerTable 2 Breakdown of International HIV Dementia Scale
(IHDS) Scores
Mean (SD) Range (IQR) N (%)
IHDS total score 9.02 (1.39) 6-12 (8–10)
IHDS finger-tapping subscore 3.49 (0.53) 2-4 (3–4)
15 taps in 5 seconds 202 (51)
11-14 taps in 5 seconds 191 (48)
7-10 taps in 5 seconds 6 (2)
3-6 taps in 5 seconds
0-2 taps in 5 seconds
IHDS alternating hand sequence 2.25 (0.57) 1-4 (2–3)
4 sequences in 10 seconds 1 (0.25)
3 sequences in 10 seconds 125 (31)
2 sequences in 10 seconds 246 (62)
1 sequences in 10 seconds 27 (7)
0 sequences in 10 seconds
Unable to perform
IHDS 4-word recall 3.28 (0.77) 1-4 (3–4)
4 words recalled 182 (46)
3 words recalled 152 (38)
2 words recalled 58 (15)
1 word recalled 7 (2)
Abbreviations: IHDS International HIV Dementia Scale, IQR Interquartile range,
SD Standard deviation.taps in 5 seconds and only 2% completed 10 or fewer
finger taps in 5 seconds.
Correlates of a positive dementia screen
The socio-demographic correlates of a positive dementia
screen are presented in Table 3 and Table 4. In bivariable
analyses with a cut-off of ≤10, the factors that appeared
to be associated with a positive screen included being
of female gender, increasing age, having only primary
education (compared to greater than primary education),
being previously married or currently married/co-ha-
biting (when compared to having never been married),
having a diagnosis of depression within the past year,
and having symptoms associated with HIV-infection
(Table 3). However, after adjusting for potential con-
founding by each of the previously cited factors, only
marital status, education and having symptoms associ-
ated with HIV-infection remained significant predictors
of a positive dementia screen (Table 4).
After adjustments, the odds of having a positive screen
in previously married participants was 2.56 times (95%
CI: 1.06, 6.18) that in currently married/co-habiting par-
ticipants. Also, the odds of a positive screen in partici-
pants with greater than primary level education was 0.12
times (95%CI: 0.06, 0.26) that in participants with only
primary education. The strongest predictor of a positive
screen was the presence of symptoms associated with
HIV-infection: after adjustment, the odds of having a posi-
tive screen in symptomatic participants was 12.16 times
(95% CI: 3.08, 48.05) that in asymptomatic participants.
Discussion
In this study we report a high prevalence of a positive
screen for dementia using the IHDS with more than half
of participants on ART in Bamenda screening positive.
We also show that the primary function that appears im-
paired, based on this screening tool, is psychomotor
speed while motor speed and memory recall are relatively
better preserved. Few predictors of poor neurocognitive
function were identified, with HIV-symptomatology being
the strongest and the others being marital status and level
of education.
To the best of our knowledge this is one of the few
studies documenting and characterising the type of
neurocognitive disorders in patients already on antire-
trovirals in sub-Saharan Africa. Our positive screen
prevalence estimate is very much higher than the 21%
reported by Njamnshi et al., in HIV-positive patients in
Yaounde, Cameron [6]. Our estimate is however very
similar to the 80% reported by Robbins et al., in a popu-
lation of patients on ART in South Africa [14]. Other
studies conducted in Africa indicated lower screen posi-
tive rates: 22% in ART naïve patients in Lusaka, Zambia
[15]; 14% in a mix of ART-naïve and experienced












Female 2.16 1.24, 3.77 −0.68 −0.99, -0.3
Age
20–29 REF REF REF
30–39 2.44 1.17, 5.08 −0.35 −0.78, 0.07
40–49 3.75 1.75, 8.08 −0.89 −1.31, -0.46
50+ 12.09 3.29, 44.43 −1.67 −2.15, -1.19
Marital Status
Married/co-habitating REF REF
Previously married 3.22 1.56, 6.65 −0.64 −0.93, -0.35
Never married 0.48 0.26, 0.89 0.66 0.31, 1.01
Education
Primary REF REF
Greater than primary 0.10 0.05, 0.19 1.52 1.29, 1.76
Depression diagnosis
Past month 0.52 0.13, 2.01 0.45 −0.38, 1.28
Past 6 months 0.44 0.16, 1.19 0.67 0.04, 1.29
Past year 0.41 0.18, 0.94 0.69 0.17, 1.21




1 1.25 0.53, 2.95 0.004 −0.41, 0.41
2+ 0.73 0.38, 1.38 0.11 −0.24, 0.46
HIV Symptoms
0 REF REF
1–4 5.60 1.79, 18.58 −1.08 −1.84, -0.32
5–9 16.00 4.68, 54.73 −1.52 −2.28, -0.76
10+ 19.20 3.10, 119.05 −1.88 −2.78, -0.99
HIV Symptoms
0 REF REF
>0 9.05 2.86, 28.62 −1.33 −2.09, -0.58
HIV Symptom Score* 1.28 1.14, 1.44 −0.11 −0.16, -0.07
Village of residence
Urban REF REF
Rural 1.46 0.83, 2.56 −0.30 −0.58, -0.02
Abbreviations: *For each additional symptom; CI Confidence interval, IHDS
International HIV Dementia Scale, IQR Interquartile range, REF Reference
category, SD Standard deviation.















Female 1.92 0.92, 3.99 −0.48 −0.75, -0.22
Age
20–29 REF REF
30–39 2.05 0.86, 4.89 −0.17 −0.53, 0.19
40–49 2.43 0.91, 6.49 −0.48 −0.86, -0.11





Previously married 2.56 1.06, 6.18 −0.31 −0.57, -0.06
Never married 0.73 0.34, 1.56 0.25 −0.07, 0.56
Education
Primary REF REF
Greater than primary 0.12 0.06, 0.26 1.1 0.91, 1.38
Depression diagnosis
Past year 0.49 0.17, 1.41 0.37 −0.04, 0.78
HIV Symptoms
0 REF REF
>0 12.16 3.08, 48.05 −0.97 −1.59, -0.35
Village of residence
Urban REF REF
Rural 1.22 0.63, 2.36 −0.14 −0.35, 0.08
Abbreviations: CI Confidence interval, IHDS International HIV Dementia Scale,
IQR Interquartile range, REF Reference category, SD Standard deviation.
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for at least six months) [16]; 38% in HIV-positive
patients in Gaborone, Botswana (97.5% of whom were
ART-experienced) [17].
It is not immediately clear to us why such a high positive
screen rate was recorded. However, amongst others, we
suspect that this could be an indication of a truly high
prevalence of neurocognitive disorders in these patients
who were already on antiretroviral therapy, an indication of
relatively advanced HIV-disease. It is worthwhile noting
that in this setting antiretroviral therapy was only
recommended in patients with CD4+ counts less than 200
or having an AIDS-defining illness (WHO stage IV).
The high screen positive rate could also potentially be
due to the IHDS performing poorly (with a low speci-
ficity thus high false positivity rate) in this population.
This poor performance could be linked to the use
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cause peripheral neuropathy which could potentially
reduce psychomotor speed. It is worthwhile noting that
a vast majority of the patients in this clinic were on
non-nucleotide reverse transcriptase inhibitor (NNRTI)-
based antiretroviral therapy, with the NNRTI being com-
bined with two nucleotide-based reverse transcriptase
inhibitors (NRTI). Zidovudine and lamivudine are the
most commonly used NRTI and have been shown to
have neurologic side-effects that include peripheral
neuropathy [4]. Efavirenz is also commonly used and has
been shown to have CNS effects [4].
The poor performance by the IHDS could also be linked
to the education status of participants. In an analysis of the
performance of IHDS, Waldrop-Valverde et al., showed that
only education was significantly associated with perform-
ance [18]. Further, a study by Nitrini et al., showed that per-
formance on the AHS was inversely correlated with the
number of years of schooling [19]. We note however that
Sacktor et al. found no effect of educational level on the
performance of the IHDS [13].
Though widely used, further studies are needed to val-
idate the IHDS particularly in a large sample of patients
on antiretroviral therapy and moderate to low education
status [18,20,21]. This validation is particularly import-
ant as other authors have reported that certain screening
tests may not be appropriate in certain populations. For
example Robbins et al. in their assessment of the utility
of the Montreal Cognitive Assessment scale reported
that it may need to be modified before being used in
South Africa [22].
Few studies have examined correlates of neuro-
cognitive disorders in patients on ART. Lawler et al. [17]
identified level of education and age (and not CD4
count) as significant correlates of disorders in patients
in Botswana. Patel et al. [16]identified male gender
and education level as risk factors associated with
neurocognitive disorders. Joska et al. also confirmed
older age and low education level as factors associated
with HAND in South Africa [23]. Njamnshi et al. [24]
reported advanced clinical diseases, low CD4 counts and
low haemoglobin levels as risk factors for HAND in
HIV-positive subjects in Yaounde, Cameroon. The latter
findings are consistent with our findings of positive screen
being correlated with increased HIV-symptomatology, in-
dicative of relatively advanced disease.
While validity of our findings is vouched, amongst
others, by the use of a well-trained health personnel in
administering the IHDS, the use of a calm and re-
assuring milieu while assessing the participants, the ad-
equately large sample size of participants on antiretro-
viral therapy, and controlling for some confounding in
the assessment of correlates, a number of limitations
need to be considered in interpreting these data. First,the study is based on a screening tool, not a diagnostic
tool – we did not systematically perform a diagnostic as-
sessment and some of the positive screens could effect-
ively be false positives. This limitation leads one to argue
for a better assessment of not only the validity of the
IHDS as a tool for screening for dementia in this popu-
lation, but also for further prospective studies that evalu-
ate the long-term evolution of patients who at some
point screen positive for HAND. Only then will it be
possible to make a recommendation on the utility, or
lack thereof, of systematically screening in this popula-
tion using the IHDS.
Other limitations include the lack of detailed informa-
tion on HIV-disease such as CD4+ cell count levels and
HIV-viral load at the time of study enrolment. However,
the fact that these patients were on antiretroviral therapy
and the high prevalence of symptoms suggest that the
participants must have had advanced HIV-disease. The
findings are certainly only representative of patients on
antiretroviral therapy attending HIV-clinics like that of
the Bamenda Regional Hospital. Some potential predic-
tors could also have been missed as not all characteris-
tics were assessed. The latter could also imply a limit on
the adjustment for unmeasured confounders such as
HIV-viral load.
Conclusion
If confirmed, our findings suggest that neurocognitive
disorders may be a significant concern in HIV-infected
patients in settings such as ours. These disorders appear
more prominent in patients with symptomatic diseases.
Nevertheless further studies assessing the validity of the
IHDS compared to a more specific gold-standard, and
prospective studies describing the long term outcomes
of a positive screen, as well as the effectiveness of early
interventions on these outcomes will be needed for the
development of guidelines specific to this population.
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